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The maternal immune response is essential for successful pregnancy, promoting immune tolerance to the fetus while maintaining
innate and adaptive immunity. Uncontrolled, increased proinflammatory responses are a contributing factor to the pathogenesis of
preeclampsia. The Th1/Th2 cytokine shift theory, characterised by bias production of Th2 anti-inflammatory cytokine
midgestation, was frequently used to reflect the maternal immune response in pregnancy. This theory is simplistic as it is based
on limited information and does not consider the role of other T cell subsets, Th17 and Tregs. A range of maternal peripheral
cytokines have been measured in pregnancy cohorts, albeit the changes in individual cytokine concentrations across gestation is
not well summarised. Using available data, this review was aimed at summarising changes in individual maternal serum
cytokine concentrations throughout healthy pregnancy and evaluating their association with preeclampsia. We report that TNF-
α increases as pregnancy progresses, IL-8 decreases in the second trimester, and IL-4 concentrations remain consistent
throughout gestation. Lower second trimester IL-10 concentrations may be an early predictor for developing preeclampsia.
Proinflammatory cytokines (TNF-α, IFN-γ, IL-2, IL-8, and IL-6) are significantly elevated in preeclampsia. More research is
required to determine the usefulness of using cytokines, particularly IL-10, as early biomarkers of pregnancy health.
1. Introduction
The importance of the maternal immune system in the estab-
lishment and maintenance of successful pregnancy is well
researched. The maternal immune system must support
immune tolerance to the fetus while maintaining innate
and adaptive responses to prevent pathogen invasion. There
are key roles for immune cells during pregnancy, particularly
uterine natural killer cells (uNK) at the implantation site [1]
and at the maternal-fetal interface [2], mediating important
processes involved in placentation, for example, angiogene-
sis. Research exploring the maternal-fetal interface dates
back to 1953 when Medawar defined the fetus as an allograft
[3] and the uterus was originally proposed to be an immune
privileged site [4]. Further theories exist on how the maternal
immune response adapts to pregnancy and enables survival
of the fetus including the proposed anatomical barrier effect
between the mother and fetus [5], maternal systemic and
local immune suppression, a lack of major histocompatibility
complex (MHC) antigens on fetal tissue, and the maternal
Th1/Th2 cytokine shift [6]. Research has focused on the
maternal cytokine profile and how it differs during preg-
nancy, suggesting that a balance between pro- and anti-
inflammatory responses is important for optimal pregnancy
outcome [7].
Cytokines are signalling proteins directing biological pro-
cesses throughout pregnancy, from implantation to parturi-
tion. The first trimester is a vulnerable stage of pregnancy
as complications can be linked back to abnormal placental
development [8]. While implantation and placental develop-
ment are proinflammatory processes, the maternal immune
response acts to control inflammation through regulatory
and anti-inflammatory mediators [9]. The pregnancy “Th2-
like phenomenon” was first described by Wegmann and
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colleagues, proposing a bias towards Th2 cytokine produc-
tion to achieve immune tolerance to the fetus [10]. Research
using isolated peripheral blood mononuclear cells (PBMCs)
from pregnant women between the first and third trimester
suggested a “shift” towards Th2 cytokine production during
healthy pregnancy compared to nonpregnant women [11].
Following extensive research, the proposed Th1/Th2 gesta-
tional cytokine shift was characterised by increased anti-
inflammatory Th2 cytokine production in the second trimes-
ter [1, 12]. Furthermore, adverse pregnancy complications
including preeclampsia have been associated with increased
Th1 proinflammatory cytokines [13, 14]. In recent years,
however, the Th1/Th2 cytokine profile has been deemed
too simplistic. Research now focuses on many contributing
mediators of the immune response including regulatory T
cells (Tregs) [15] and Th17 cells [16]. A recent review sum-
marised how an imbalance between maternal proinflamma-
tory cytokines and immune regulatory factors (Tregs and
IL-10) is a key contributor to preeclampsia [17]. An in-
depth understanding of the changes in the maternal cytokine
profile could distinguish successful pregnancy from preg-
nancy complications and help provide a greater understand-
ing of the immune response during pregnancy.
Alterations in the normal immune response during preg-
nancy may contribute to the onset of pregnancy complica-
tions. Hypertensive conditions occur during approximately
10% of pregnancies in the UK with a wide variation in inci-
dence worldwide [18]. In women with normal blood pressure
prior to pregnancy, preeclampsia is characterised by hyper-
tension and proteinuria or hypertension with end organ dys-
function with or without proteinuria [19, 20]. The disorder,
which develops at ≥20 weeks, is associated with infant com-
plications including fetal growth restriction [21]. Uncon-
trolled, increased proinflammatory responses alongside less
regulatory or anti-inflammatory cytokines are important
contributing factors to the pathogenesis of preeclampsia
[22], and the maternal cytokine profile has been shown to
differ between normotensive pregnancy and preeclampsia
[23–25]. Research has shown differences in cytokine concen-
trations in early pregnancy between healthy women and those
who later developed preeclampsia, suggesting that cytokines
may be early predictors of preeclampsia [26]. As a result, it is
plausible that maternal cytokine concentrationsmay be poten-
tial predictors of adverse pregnancy complications.
Although the maternal immune response is well
researched, the change, if any, in individual peripheral cyto-
kines across gestation has not been well summarised. In the
past, cytokines have been difficult to detect in maternal plasma
[27] and serum [28] from healthy pregnancy, but advances in
technology over time has improved the sensitivity of immuno-
assays used to measure cytokines. Using available data from
the current literature, this review was aimed at summarising
changes in individual maternal serum cytokine concentrations
throughout healthy pregnancy and evaluating associations
between maternal serum cytokines and preeclampsia.
2. Methods
The research strategy utilised Ovid/Medline databases. Ini-
tial literature searches were conducted between 8th May
and 7th June 2019. The search was repeated on the 15th
April 2020. Figure 1 summarises the results of our literature
search and the papers retained or excluded. Human studies
published in the English language on or after 2009 were
included if cytokines were measured in maternal serum
from a cohort of ≥50 healthy pregnant women or at >1
Ovid/medline literature search:
n = 5401 papers
Excluded:
Limits applied: English language &
human studies
n = 3402 retained
Review articles were excluded
n = 3182 retained
Results limited to 2009-2020
n = 1838ǂ retained
Title, abstract and full text
screening
n = 1709 excluded













samples (n = 356)
Animal or cell culture (n = 423)
Other biological samples⁎ (n = 293)
Not pregnant or not relevant⁎ (n = 206)
Not relevant peripheral cytokines⁎
(n = 140)
<50 healthy pregnant & no
preeclampsia (n = 113)
Cannot access/missing information
(n = 31)
Duplicates (n = 2)
Data not available (n = 54)
Other⁎ (n = 91)
Figure 1: Summary of the literature search and papers retained or excluded. ⱡIncluding four additional papers identified from references. ∗
Other biological samples: e.g., plasma, whole blood, CSF, and PBMCs; not pregnant or not relevant: e.g., IVF, recurrent miscarriage, fertile
and infertile women, and infection or periodontitis/gingivitis; not relevant peripheral cytokines: e.g., gene polymorphisms or expression;
other included not healthy pregnancy or preeclampsia and adolescent or twin pregnancy.
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time point across the three trimesters, regardless of sample
size. To obtain data on preeclampsia, the same inclusion
criteria were applied with the exception that there was no
restriction on sample size.
Exclusion criteria were cytokines measured in other bio-
logical samples (e.g., plasma, whole blood, or PBMCs),
murine or in vitro models, where there was a different group
of participants per sampling time point, and studies which
did not report cytokine data (e.g., data were only presented
in graphs). Four additional papers were included from the
references of studies. Owing to the high volume of papers
identified (n = 1838), we excluded studies consisting of <50
healthy pregnant women. For this review, cytokine concen-
trations were obtained from published work, converted to
pg/mL for standardisation where possible, expressed as
median unless otherwise stated, and reported to 2 decimal
places. The gestational age of sample collection is provided
where possible based on the mean or median as stated in
the original paper and rounded to the nearest whole number.
The following cytokines are discussed in this review: IFN-γ,
TNF-α, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-13, IL-
17, IL-18, IL-33, and TGF-β. The existing data for cytokine
concentrations within healthy pregnancy are displayed in
Tables 1 and 2 while data for women who developed
preeclampsia are in Table 3.
3. Cytokines in Healthy Pregnancy
Interferon-gamma (IFN-γ) is a proinflammatory cytokine
secreted as part of the immune response to damage-
associated molecular patterns (DAMPs) or pathogen-
associated molecular patterns (PAMPs), by immune cells
including natural killer (NK) and Th1 cells [29]. The active
protein interacts with a heterodimeric receptor comprising
IFN-γR1 and IFN-γR2, resulting in the activation of the
JAK-STAT signalling pathway to coordinate immune
responses [30]. IFN-γ is a key mediator in response to viral
pathogens [31, 32] and tumours [33]. At the maternal-fetal
interface, IFN-γ contributes to the establishment and main-
tenance of successful pregnancy, mediating endometrial vas-
cular remodelling and angiogenesis [34]. One study observed
significant increasing mean concentrations of IFN-γ between
the first, second, and third trimesters of healthy pregnancy
(91.05 pg/mL, 124.50 pg/mL, and 131.05 pg/mL, respec-
tively) [35], while others reported significantly lower IFN-γ
concentrations in the third trimester compared to the first
[36, 37] and second [38] trimesters. Another study detected
higher IFN-γ concentrations in the third trimester compared
to the second [39]. The study participants, however, were
overweight and obese which may have influenced their
results as obesity is associated with elevated cytokine concen-
trations including IFN-γ [40]. High IFN-γ concentrations
may also reflect subclinical or asymptomatic infections.
Owing to the antiviral activity of IFN-γ, controlling for infec-
tions is an important factor which restricts comparability of
data. While some studies included in this review adjusted
for the presence or absence of infection or took infection into
consideration when including/excluding participants [38,
41], others did not specify this criterion [39, 42]. Meanwhile,
a recent study showed no significant change in maternal
serum IFN-γ concentrations across 4 time points (10, 12,
19, and 24 weeks) [43]. From the existing data discussed,
there is no obvious trend or pattern to the changes in IFN-
γ and any changes observed may reflect the role of IFN in
inflammation owing to infection.
Tumour necrosis factor (TNF)-α is a proinflammatory
cytokine which is encoded on chromosome 6 and acts
through TNF receptors (TNFR1 and TNFR2) expressed by
most cells of the immune system [44]. Apart from its key role
in inflammatory responses against infection [45], TNF-α is
an important regulator of normal cell function, influencing
vital biological processes including cell proliferation [46],
apoptosis [47], and the production of other cytokines such
as IL-6 [48]. Apoptosis is a critical process to regulate pla-
centa trophoblast cell survival in normal pregnancy [49].
TNF-α binding to TNFR1 can mediate cell death through
interactions with the TRAAD adaptor protein and fas-
associated death domain (FAAD) or survival through the
binding of TRAAD, TNF receptor-associated factor (TRAF),
and the receptor interaction protein [50]. In healthy preg-
nancy, maternal serum TNF-α concentrations are signifi-
cantly higher in the second and third trimesters compared
to the first [51]. Another study found that mean TNF-α con-
centrations significantly increased between the first, second,
and third trimesters of healthy pregnancy (108.00 pg/mL,
153.01 pg/mL, and 172.89 pg/mL, respectively) [35]. Others
have also observed significantly higher TNF-α concentra-
tions in the third trimester compared to early pregnancy
[52, 53]. Significant increases in maternal serum TNF-α con-
centrations are also reported between the first and second
[54, 55] and the second and third trimesters [56]. In con-
trast, others detected a significant reduction in maternal
serum TNF-α concentrations between the first and third tri-
mesters [36, 37]. There is also evidence of no change in
TNF-α between various time points across healthy preg-
nancy [38, 43, 57–61]. Overall, it is likely that TNF-α con-
centrations increase as gestation progresses albeit not
excessively and may support the increased metabolic needs
associated with pregnancy.
Interleukin-6 (IL-6) is a pleiotropic cytokine largely pro-
duced by monocytes and macrophages but also by other
immune and nonimmune cells including T cells and endo-
thelial cells. In the innate immune response, macrophages
secrete IL-6 in response to PAMPs which are bound to pat-
tern recognition receptors. When secreted, IL-6 moves to
the liver where it stimulates production of acute phase pro-
teins such as C-reactive protein (CRP) [62], thereby promot-
ing inflammation. IL-6 mediates embryo implantation and
placental development [63]. Maternal serum IL-6 concentra-
tions significantly increase during healthy pregnancy [64].
Others also reported significantly higher IL-6 concentrations
in the third trimester in comparison to samples collected ear-
lier in pregnancy [35, 59, 65, 66]. Repeated sampling in the
first half of healthy pregnancy has shown that IL-6 concen-
trations decrease between the first and second trimesters
[43]. In contrast, data from another study suggests the oppo-
site, reporting higher IL-6 concentrations in the second
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several studies in this review found that IL-6 concentrations
significantly increase during healthy pregnancy, others
reported no significant change [36, 38, 55, 56, 61, 67–70].
Th17 cells are important for coordinating innate and
adaptive immune responses against invading pathogens and
are involved in the development of autoimmunity. IL-17
(IL-17A) and IL-17F are better understood compared to
other members of the IL-17 cytokine family. IL-17 cytokines
are secreted by Th17 cells and promote production of other
proinflammatory cytokines which, if unregulated, 5can con-
tribute to the development of autoimmune conditions [71].
One study reported that IL-17 concentrations significantly
increase with gestation; however, IL-17 was detected in all
three trimesters in only three out of 13 women [72], indicat-
ing that serum IL-17 may be difficult to detect in healthy
pregnancy. A larger study found that IL-17 concentrations
significantly decrease between the first and second trimesters
of healthy pregnancy [43]. Meanwhile, data from another
cohort showed significant variation in IL-17 concentrations
across 5 time points throughout healthy pregnancy but
reported no “obvious trend” [73]. Owing to few studies mea-
suring maternal serum IL-17 at multiple time points, there is
not enough data to understand specific changes during
healthy pregnancy. Although not within the scope of this
review, recent research examined the importance of the
“Th17/Treg” paradigm in pregnancy, whereby the altered
Th17 : Treg ratio (reduced Treg cells) may contribute to
preeclampsia [16].
Interleukin-1 beta (IL-1β) is similar in structure and
function to IL-1α, and both proteins are encoded by genes
located on chromosome 2 and act through binding to the
type 1 IL-1 receptor (IL-1R1) to elicit proinflammatory
responses [74]. In response to stimuli, including DAMPs or
PAMPs, IL-1β is secreted by immune cells including mono-
cytes and macrophages [75]. IL-1β is a Th1 cytokine but is
also associated with Th17 responses [76]. Existing data sug-
gests that IL-1β is typically present at low concentrations in
maternal serum during healthy pregnancy with fewer studies
detecting concentrations above 10 pg/mL [24, 41, 51, 77–79].
A study showed that IL-1β is significantly higher in mater-
nal serum within the second and third trimesters compared
to the first [51], while others indicate that IL-1β signifi-
cantly decreases between the first and third trimester [36,
37]. In contrast, there is also data supporting no significant
change in maternal serum IL-1β concentrations across var-
ious time points of healthy pregnancy [43, 56]. Such con-
flicting results may be explained by difficulty in detecting
significant changes in IL-1β because of its short half-life
in circulation [75, 80].
The proinflammatory cytokine, interleukin-2 (IL-2), acts
by binding to the IL-2R, influencing T lymphocyte differenti-
ation into effector and memory T cells as well as regulatory T
cells which are important for preventing autoimmunity [81].
Evidence suggests that there is a significant reduction in
maternal serum IL-2 concentrations between the first and
third trimester of healthy pregnancy [36, 37]. The existing
data on maternal serum IL-2 concentrations is limited and
may be owing to difficulty in detecting the cytokine in
healthy pregnancy as studies have noted concentrations
below the lower limit of detection (<LLOD) [25, 66, 82].
IL-2 does not appear to be present at high concentrations
in healthy pregnancy but is elevated in women who develop
complications including preeclampsia [83] which is dis-
cussed in more detail later in this review.
The inflammatory chemokine, interleukin-8 (IL-8), sig-
nals through binding CXCR1 and CXCR2 to promote
recruitment of immune cells such as neutrophils and macro-
phages to sites of inflammation [84]. IL-8 mediates angiogen-
esis in vitro [85] which is an important process in pregnancy
for fetal development [86]. In healthy pregnancy, IL-8 has
been shown to decrease with gestational age during the first
half of pregnancy [43] but significantly increase between
the second and third trimesters [38]. Another study found
higher, albeit nonsignificant, concentrations in the third tri-
mester compared to the second trimester [56]. These changes
in IL-8 concentrations may reflect the Th1/Th2 cytokine
shift, indicating reduced proinflammatory responses in the
second trimester, but the immune profile returns to more
proinflammatory responses towards the end of pregnancy.
Meanwhile, a study found that IL-8 significantly decreased
between the first and third trimesters of healthy pregnancy
[36]. While most research has detected significant changes,
a smaller study reported no change between the first and
third trimesters [37] which may indicate a lack of power
within the study design.
IL-12 is a proinflammatory cytokine important in regu-
lating both innate and adaptive immune responses including
the differentiation of Th1 cells [87]. Thus, IL-12 plays an
important role in the regulation of Th1 immune responses.
The IL-12 cytokine consists of two subunits (p35 and p40)
encoded by separate genes on chromosomes 3 (IL-12A) and
5 (IL-12B), respectively, and the resulting biologically active
heterodimer is IL-12p70 [88]. A significant reduction in
maternal serum IL-12 concentrations has been observed
between the first and third trimesters of healthy pregnancy
[36, 37]. IL-12p70 concentrations are similar between the
first and second trimesters [43] and second and third trimes-
ters [66]. Therefore, IL-12 may be lower in the third trimester
compared to the first, but because of limited data as no study
measured IL-12 within all three trimesters of healthy preg-
nancy, specific changes are not well understood.
Interleukin-10 (IL-10), encoded on chromosome one, is
an anti-inflammatory cytokine and acts through a receptor
complex consisting of IL-10R1 and IL-10R2 [89]. The multi-
functional cytokine is produced by macrophages, mast cells,
Th2 cells, and regulatory T cells (Tregs) and can inhibit pro-
inflammatory cytokines including IFN-γ [90]. IL-10 and
TGF-β are secreted by Tregs, and their immunomodulatory
properties control inflammation which is important for suc-
cessful pregnancy. Tregs are essential for the maintenance of
healthy pregnancy, and IL-10 is known to mediate Treg
development [91]. In healthy pregnancy, maternal serum
IL-10 concentrations significantly decrease between the first
and second trimesters [43] and between the second and third
trimesters [38], although the difference in concentration
values were subtle. Others reported significantly higher IL-
10 concentrations in the third trimester compared to the first
[51] and second [53]. Notably, there is also evidence of no
23Journal of Pregnancy
significant change in IL-10 concentrations during healthy
pregnancy [36, 61, 66, 67, 92]. Overall, IL-10 concentrations
may increase in the third trimester of healthy pregnancy or
remain consistent throughout pregnancy.
IL-4 mediates differentiation of naive T cells into Th2
cells and acts as an anti-inflammatory cytokine by binding
to its receptor, IL-4Rα, and activating the STAT6 signalling
pathway [93]. In healthy pregnancy, maternal serum IL-4
concentrations appear to remain constant throughout gesta-
tion [43, 53]. Others that have measured IL4 did not look for
differences in concentrations across pregnancy [94] while
some report that IL-4 is below the LLOD in healthy preg-
nancy [38, 66]. Although there is limited research, IL-13
[38, 43] and IL-33 [95] concentrations also remain consistent
during healthy pregnancy. IL-5, IL-7, IL-9, IL-15, and IL-31
were not discussed in this review due to limited data and/or
did not appear to have a relevant role in healthy pregnancy
or preeclampsia.
4. Serum Cytokines as Early
Biomarkers of Preeclampsia
There is increasing interest in the role of cytokines as early
biomarkers of preeclampsia. Studies have measured maternal
serum cytokines in samples collected prior to the onset of
preeclampsia and examined the difference between women
who later developed preeclampsia and women who remained
healthy. For TNF-α, while evidence suggests serum concen-
trations do not significantly differ between those who later
developed preeclampsia and women who remained healthy
[42, 58, 77, 96], others report that TNF-α measured at 14-
18 weeks may be a potential biomarker for the onset of pre-
eclampsia with lower concentrations of TNF-α observed in
women who later developed preeclampsia [97].
In early pregnancy (10-14 weeks), IL-1β significantly dif-
fers between women who develop preeclampsia and those
who remain healthy (data not in tables as concentration
was presented as a multiple of the gestational median value
(MoM) ratio) [26]. Furthermore, in maternal samples
obtained in the second trimester (approx. 17 weeks), IL-1β
is reportedly higher in healthy pregnancy compared to
women who developed preeclampsia, with higher IL-1β con-
centrations in the second trimester associated with decreased
odds of developing preeclampsia [58, 77]. On the other hand,
first trimester IL-1β concentrations have been linked to pre-
term birth associated with preeclampsia (<37 weeks) [58],
but not with those who only developed preeclampsia [42,
58, 96]. Overall, IL-1β may be an early predictor for pre-
eclampsia resulting in preterm delivery albeit more research
is needed.
Research has shown no difference in maternal serum IL-
8, IL-12, or IL-6 concentrations between women who later
developed preeclampsia and women with healthy pregnancy
[42, 77]. In the first trimester, a study found significantly
higher serum IL-8 concentrations in women who developed
preeclampsia but no difference in IL-12p40, IL-12p70, or
IL-6 compared to women with healthy pregnancy [96]. In
women who went onto developing preeclampsia, another
study found that those with samples collected in the first tri-
mester had significantly higher IL-12 and IL-6 concentra-
tions while women with second trimester serum samples
had higher IL-8 [58]. From our literature search, there are
some data indicating that IL-8, IL-12, and IL-6 may be early
predictors for the onset of preeclampsia, but more research
would be required to confirm these existing findings.
In samples obtained in the first trimester, some evidence
suggests that IL-10 concentrations are significantly higher in
women who developed preeclampsia compared to women
with healthy pregnancy [65 58], while others indicate no sig-
nificant difference [42, 96]. In samples collected in the second
trimester, IL-10 is significantly lower in women who later
develop preeclampsia compared to women who remain
healthy [58, 77, 97, 98]. Furthermore, mean IL-10 concentra-
tions at 14-18 weeks are also significantly lower in women
who developed severe preeclampsia (21.54 pg/mL) compared
to women with mild preeclampsia (14.84 pg/mL) [98].
Another study, however, reported no difference in IL-10 at
14-18 weeks between women who later developed pre-
eclampsia and women who did not [99]. Most studies which
reported significant differences had larger cohorts with >50
women who developed preeclampsia [58, 77, 98], while stud-
ies that reported no significance consisted of <15 women in
the preeclampsia group [49, 96, 99]. It may be important to
consider differences in power between these studies. Overall,
several studies suggest that lower IL-10 concentrations in the
second trimester (14-18 weeks) may be an early predictor for
the onset of preeclampsia.
IL-18 concentrations in the second trimester are higher
in women who develop preeclampsia compared to controls
[77]. Maternal serum TGF-β concentrations in the first [58]
and second [77] trimesters are higher in women who devel-
oped preeclampsia compared to controls. In contrast,
another study found that women who developed preeclamp-
sia had lower TGF-β concentrations in the second trimester
which was significantly associated with preeclampsia [58].
This observation aligns with the studies previously men-
tioned that reported significantly lower IL-10 concentrations
in women who later developed preeclampsia [58, 77, 97, 98],
which may reflect the dual importance of Treg cytokines IL-
10 and TGF-β in successful pregnancy. It is important to
consider limitations associated with measuring TGF-β in
serum as platelets have a large amount of TGF-β in their
granules [100]; when serum is obtained without anticoagu-
lant platelet, degranulation may occur and result in higher
concentrations of TGF-β. Overall, lower maternal serum
IL-10 concentrations in the second trimester may be associ-
ated with the onset of preeclampsia, which may reflect the
importance of anti-inflammatory and Treg cytokines in
controlling inflammation midgestation.
5. Cytokines in Preeclampsia
Cytokines are frequently measured within the third trimester
for comparison between women suffering from preeclampsia
and healthy pregnant controls. Several studies reported sig-
nificantly higher IFN-γ concentrations in preeclampsia com-
pared to healthy pregnancy [24, 79, 101]. Increased IFN-γ
concentrations in preeclampsia may reflect increased viral
24 Journal of Pregnancy
immune responses or natural killer cell activity, as infection
is associated with preeclampsia [102] and could subsequently
result in the promotion of proinflammatory pathways and
pregnancy complications. Others, however, found signifi-
cantly lower IFN-γ concentrations in women with pre-
eclampsia [103] or no significant difference between
preeclampsia and healthy pregnant women [104–107]. From
the literature discussed in this review, the larger studies
found significantly higher IFN-γ concentrations [24, 79,
101] and it is likely that IFN-γ is elevated during the third tri-
mester in women with preeclampsia compared to healthy
pregnant women. The largest study found significantly
higher concentrations, but their study design consisted of a
wider sampling time period (25-36 weeks) [101].
In the third trimester, several studies report significantly
higher maternal serum TNF-α concentrations in women
with preeclampsia compared to controls [24, 101, 108–115]
while others have detected similar or nonsignificantly differ-
ent concentrations [103, 105, 106, 116]. Variation in study
design may have contributed to the differences in findings,
for example, sample size, methodology used to measure cyto-
kine concentrations, and exclusion criteria (including mater-
nal infection, preexisting or subclinical illnesses, and
smoking). Studies indicating no significant difference in
TNF-α concentrations between preeclampsia and healthy
pregnancy had smaller cohorts (<40 participants) [103,
116] than most studies showing that TNF-α is significantly
higher in preeclampsia (≥40 participants) [24, 101, 109–
112]. The largest study we identified showed higher TNF-α
concentrations in women with preeclampsia (n = 300) than
in healthy controls (n = 200) excluding smokers and those
with urinary or respiratory infections [101], while others
who did not find significant differences did not state if they
controlled for these factors [103, 105]. Another study
observed lower, but not statistically significant, serum TNF-
α concentrations in women with preeclampsia compared to
women with healthy pregnancy at ≥20 weeks [117]. The
study consisted of a small sample size (healthy n = 24 and
preeclampsia n = 31) and, as the sampling period crossed
between the second and third trimesters, it may have been
important to stratify participants by mild/severe- or early/-
late-onset preeclampsia. Overall, most work indicates that
TNF-α concentrations are higher in preeclampsia compared
to healthy pregnant women, reflecting the enhanced proin-
flammatory systemic environment.
Maternal serum IL-2 concentrations are significantly
higher in preeclampsia compared to healthy pregnant
women [24, 79, 101, 114]. Elevated IL-2 concentrations
may reflect the proinflammatory environment associated
with preeclampsia. Research using a murine model of placen-
tal ischemia in pregnancy proposed that IL-2 is a key cyto-
kine mediating natural killer cell activation and placental
health in preeclampsia [118]. Others, however, reported no
difference in IL-2 concentrations between preeclampsia and
healthy pregnancy [103–106].
Multiple studies observed significantly higher IL-8 con-
centrations in preeclampsia compared to healthy pregnancy
[24, 79, 104, 119], while others report no significant differ-
ence [25, 103]. Inconsistent findings may be owing to the
sampling time point as those who did not find a significant
difference collected samples earlier (30-33 weeks) [25, 103]
than 37 weeks [24, 79, 119]. Most evidence indicates higher
IL-6 concentrations in preeclampsia compared to healthy
pregnancy [24, 79, 104, 111, 114, 115, 119–126], while data
from other studies show no difference between the two
groups [103, 105, 106, 116, 117, 127–129]. From the studies
examined in this review, those consisting of larger cohorts
have shown significantly higher IL-6 concentrations in pre-
eclampsia compared to controls [24, 79, 111, 115, 125].
Nonetheless, most evidence suggests that IL-8 and IL-6 are
higher in preeclampsia compared to healthy pregnant
women and may be as a result of preeclampsia.
Research suggests that IL-12p40, IL-12p70 [24, 79], IL-17
[104, 130], IL-18 [24, 79, 131], and TGF-β [132, 133] are ele-
vated in women with preeclampsia in the third trimester
compared to healthy controls. Others, however, have found
no difference in IL-12p70 [25, 104], IL-17 [117, 134], and
TGF-β [24, 79] in women with preeclampsia compared to
controls. In contrast, maternal serum TGF-β concentrations
are reportedly lower in women with preeclampsia with fetal
growth restriction compared to controls [130]. One study
reported significantly lower IL-33 concentrations in women
with preeclampsia compared to healthy pregnancy in the
third trimester [135]. With limited data for these cytokines,
more research is required to understand their importance
in preeclampsia.
IL-1β [24, 79, 103, 110, 136], IL-4 [103, 104, 106, 107], and
IL-13 [104, 132] do not appear to significantly contribute to the
pathogenesis of preeclampsia asmost research examined in this
review indicated no difference in these cytokine concentrations
between preeclampsia and healthy pregnancy in the third tri-
mester. Others, however, reported that IL-1β was significantly
higher [104, 123] or lower [25] in women with preeclampsia.
Furthermore, other studies suggest that IL-4 is significantly
higher in preeclampsia compared to healthy pregnancy [24,
79]. In preeclampsia, the proinflammatory : anti-inflammatory
ratio (IL-2: IL-4 and IFN-γ : IL-4) is elevated compared to
healthy pregnant controls [24], reflecting the more proinflam-
matory response associated with preeclampsia.
In the third trimester, most studies reported no signifi-
cant change in maternal serum IL-10 concentrations
between women with preeclampsia and healthy pregnancy
[25, 97, 103, 104, 106, 117]. In contrast, others have
detected significantly higher IL-10 concentrations in pre-
eclampsia compared to healthy pregnant women [24, 79,
107]. As preeclampsia is deemed a more proinflammatory
environment, IL-10 concentrations may be raised in
response to the inflammatory environment. Another study
showed significantly lower IL-10 concentrations in women
with preeclampsia compared to controls in the third tri-
mester [137, 138]. As IL-10 is a key cytokine in the regula-
tion of inflammation, lower IL-10 concentrations in women
with preeclampsia may suggest that IL-10 is not effectively
controlling the proinflammatory environment that occurs
during preeclampsia.
Although beyond the scope of this review, the placenta is
a key organ contributing to the inflammatory milieu during
pregnancy and immune tolerance. Regulation of immune
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interactions at the maternal-fetal interface is essential, and
the placenta microenvironment is biased towards Th2
[139]. Abnormal placenta development is a key factor in
the pathogenesis of preeclampsia [140, 141]. It is important
to consider that, in preeclampsia, there are increased proin-
flammatory cytokines in both the maternal circulation and
the placenta [17, 138].
6. Summary of Findings
We found substantial evidence of changes in cytokine con-
centrations that occur during healthy pregnancy. Figure 2
illustrates the main findings of this review. It is likely that
TNF-α increases as pregnancy progresses, IL-8 decreases in
the second trimester, and IL-4 concentrations remain consis-
tent throughout gestation. IFN-γ and IL-17 did not appear to
have an obvious trend in cytokine concentrations. We found
inconsistent or not enough data to specify changes in the
remaining cytokines. Lower IL-10 concentrations in early
pregnancy may be associated with the later development of
preeclampsia, but data collected later in pregnancy were
inconsistent. Therefore, it may be important to measure IL-
10 in early pregnancy as a predictor of the development of
preeclampsia. Most proinflammatory cytokines, particularly
TNF-α, IFN-γ, IL-2, IL-8, and IL-6, are significantly higher
in women suffering from preeclampsia compared to women
with healthy pregnancy reflecting the enhanced proinflam-
matory environment.
7. Strengths and Limitations
This review was conducted with a systematic approach and
covered a large number of research studies in this area. For
decades, cytokines have been frequently measured in periph-
eral maternal samples to examine the immune response. This
review provides a summary of the current maternal serum
cytokine data, allowing for easy comparison of cytokine con-
centrations across studies. Limitations of this review were
excluding data collected prior to 2009, studies consisting of
<50 healthy pregnant women, and cytokines measured in
other biological samples. Comparability of data between
studies may be limited by differences in study design includ-
ing varying methods used to detect cytokine concentrations
with different specificity and sensitivity limits (ELISA vs.
multiplex immunoassays), sample collection, sample storage
conditions, and duration.
8. Future Directions
Although maternal serum cytokine concentrations have been
measured in numerous cohorts, we found limited data for
several cytokines. Many studies obtained samples at one or
two trimesters of pregnancy which limited our ability to
determine change across healthy gestation for many cyto-
kines. As cytokines are a network of signalling proteins which
influence each other as well as their target cells, obtaining a
range of biological samples at multiple time points across
healthy gestation will allow for in-depth analysis on changes
in maternal cytokine concentrations. In future, more sensi-
tive methods, e.g., flow cytometry analysis, may be used
alongside peripheral cytokine assays to provide a better indi-
cation of cell subtypes and intracellular cytokine expression.
It may also be useful to examine further if IL-10 measured
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Figure 2: An illustration summarising the changes in the maternal serum cytokine profile in healthy pregnancy and preeclampsia.
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